Sana Biotechnology, Inc. (NASDAQ:SANA) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) have earned a consensus rating of “Moderate Buy” from the nine ratings firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $9.50.

Several analysts recently weighed in on SANA shares. Wedbush lifted their price target on Sana Biotechnology from $6.00 to $7.00 and gave the stock an “outperform” rating in a report on Tuesday, April 14th. Zacks Research cut Sana Biotechnology from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 3rd. HC Wainwright dropped their price objective on Sana Biotechnology from $9.00 to $7.00 and set a “buy” rating for the company in a report on Wednesday, March 4th. Weiss Ratings cut Sana Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 1st. Finally, Rodman & Renshaw assumed coverage on Sana Biotechnology in a report on Monday. They issued a “buy” rating and a $16.00 price objective for the company.

Sana Biotechnology Trading Down 8.4%

NASDAQ:SANA opened at $3.26 on Wednesday. The stock has a market cap of $880.17 million, a P/E ratio of -3.51 and a beta of 2.17. The stock has a 50 day simple moving average of $3.31 and a 200 day simple moving average of $4.00. Sana Biotechnology has a 1-year low of $1.60 and a 1-year high of $6.55.

Sana Biotechnology (NASDAQ:SANA) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.01. As a group, sell-side analysts forecast that Sana Biotechnology will post -0.59 EPS for the current year.

Hedge Funds Weigh In On Sana Biotechnology

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Mercer Global Advisors Inc. ADV acquired a new position in Sana Biotechnology in the 3rd quarter valued at $36,000. Lyell Wealth Management LP acquired a new position in Sana Biotechnology in the 3rd quarter valued at $37,000. TD Waterhouse Canada Inc. acquired a new position in Sana Biotechnology in the 3rd quarter valued at $37,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors acquired a new position in Sana Biotechnology in the 3rd quarter valued at $39,000. Finally, Rockefeller Capital Management L.P. raised its holdings in Sana Biotechnology by 74.3% in the 4th quarter. Rockefeller Capital Management L.P. now owns 9,588 shares of the company’s stock valued at $39,000 after acquiring an additional 4,088 shares in the last quarter. 88.23% of the stock is owned by institutional investors and hedge funds.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.